Early major adverse cardiovascular events following the initiation of the anti-interleukin 12/23 antibody ustekinumab. A population-based case-time-control study

MLA

Poizeau, F., et al. Early Major Adverse Cardiovascular Events Following the Initiation of the Anti-Interleukin 12/23 Antibody Ustekinumab. A Population-Based Case-Time-Control Study. Sept. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..655bf7704ddad9b91d406bdb84aae0bf&authtype=sso&custid=ns315887.

APA

Poizeau, F., Nowak, E., Kerbrat, S., Droitcourt, C., Sbidian, E., Guillot, B., Bachelez, H., Ait-Oufella, H., Oger, E., & Dupuy, A. (2019). Early major adverse cardiovascular events following the initiation of the anti-interleukin 12/23 antibody ustekinumab. A population-based case-time-control study.

Chicago

Poizeau, F., E. Nowak, S. Kerbrat, C. Droitcourt, E. Sbidian, B. Guillot, H. Bachelez, H. Ait-Oufella, E. Oger, and A. Dupuy. 2019. “Early Major Adverse Cardiovascular Events Following the Initiation of the Anti-Interleukin 12/23 Antibody Ustekinumab. A Population-Based Case-Time-Control Study,” September. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..655bf7704ddad9b91d406bdb84aae0bf&authtype=sso&custid=ns315887.